Sofiva Genomics Co.,Ltd. (TPEX:6615)
Taiwan · Delayed Price · Currency is TWD 33.95
+0.35 (1.04%)
At close: Apr 24, 2026
Sofiva Genomics Revenue
In the year 2025, Sofiva Genomics had annual revenue of 385.71M TWD, down -14.91%. Sofiva Genomics had revenue of 95.69M in the quarter ending December 31, 2025, a decrease of -7.52%.
Revenue
385.71M
Revenue Growth
-14.91%
P/S Ratio
1.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
733.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 385.71M | -67.61M | -14.91% |
| Dec 31, 2024 | 453.31M | -13.49M | -2.89% |
| Dec 31, 2023 | 466.80M | -28.98M | -5.84% |
| Dec 31, 2022 | 495.78M | -12.64M | -2.49% |
| Dec 31, 2021 | 508.42M | 19.55M | 4.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| PharmaEssentia | 15.63B |
| Kim Forest Enterprise | 549.14M |
| BioLASCO Taiwan | 262.66M |
| Puriblood Medical | 117.35M |
| Caliway Biopharmaceuticals | 38.04M |
| Neith | 36.15M |
| AmCad BioMed | 30.44M |